A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia

Journal:

Blood

Published:

2026-04-09

DOI:

10.1182/blood.2025030722

Affiliations:

23

Authors:

32

Go to article

Institutions	Authors	Share
Ulm University Medical Center, Germany	7.000000	0.22
Hannover Medical School (MHH), Germany	2.500000	0.08
German Cancer Research Center in the Helmholtz Association (DKFZ), Germany	2.000000	0.06
Berlin Institute of Health (BIH), Germany	2.000000	0.06
University Cancer Center Hamburg (UCCH), UHH, Germany	1.000000	0.03
Technical University of Munich (TUM), Germany	1.000000	0.03
Hanusch Krankenhaus - Österreichische Gesundheitskasse (ÖGK), Austria	1.000000	0.03
University of Tübingen (Uni Tübingen), Germany	1.000000	0.03
University Medical Center Freiburg, Germany	1.000000	0.03
Johannes Wesling Klinikum Minden, Germany	1.000000	0.03
Heinrich Heine University Düsseldorf (HHU), Germany	1.000000	0.03
University Hospital Bonn (UKB), Uni Bonn, Germany	1.000000	0.03
University Medical Center Schleswig-Holstein - Campus Kiel (UKSH Kiel), Germany	1.000000	0.03
Medical University of Graz (Med Uni Graz), Austria	1.000000	0.03
Medical University of Innsbruck (MUI), Austria	1.000000	0.03
Klinikum Bremen-Mitte, Germany	1.000000	0.03
University Hospitals of the Ruhr University of Bochum (UK RUB), Germany	1.000000	0.03
SLK-Kliniken Heilbronn GmbH, Germany	1.000000	0.03
Kliniken Essen-Mitte, Germany	1.000000	0.03
University Medical Center Mainz, JGU, Germany	1.000000	0.03
Barmherzigen Schwestern Krankenhaus Wien, Austria	1.000000	0.03
Ludwigshafen Hospital, JGU, Germany	1.000000	0.03
University Hospital in Halle (Saale) (UKH), MLU, Germany	0.500000	0.02

Interested in Oncology and Carcinogenesis?